Dalosirvat

Dalosirvat ( , ; developmental code name SM-04554) is a drug acting as a Wnt signaling pathway stimulant which is under development for the treatment of alopecia (hair loss).

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Dalosirvat ( , ; developmental code name SM-04554) is a drug acting as a Wnt signaling pathway stimulant which is under development for the treatment of alopecia (hair loss). It is used topically as a solution. The drug is being developed by Biosplice Therapeutics (formerly known as Samumed).

As of April 2021, it is in phase 2/3 clinical trials for this in Turkey. There have been no further updates on the development of dalosirvat as of October 2025. Two phase 2 trials have been completed and preliminary results released.

In one of the trials, only a 0.15% concentration and not a higher 0.25% concentration showed effectiveness. A 625-patient phase 3 trial was reportedly started in 2018. It was reported in a 2023 literature review that dalosirvat had completed a phase 3 trial in early 2023 and that Biosplice Therapeutics had cancelled its development based on the trial's results.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1331211074 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.